Dual antiplatelet therapy following percutaneous coronary intervention : clinical and economic impact of standard versus extended duration -- project protocol.
Current guidelines recommend that patients be given dual antiplatelet therapy (DAPT; combination of a P2Y12 inhibitor [clopidogrel, prasugrel, or ticagrelor] with acetylsalicylic acid [ASA]) ranging from six months to 12 months following percutaneous coronary intervention (PCI) with stenting, with t...
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK525821/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa :
Canadian Agency for Drugs and Technologies in Health,
2018
|
| Series: | CADTH optimal use report.
|
| Subjects: |
